Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status

Authors: Héctor Rodríguez-Angulo, Juan Marques, Ivan Mendoza, Marco Villegas, Alfredo Mijares, Núria Gironès, Manuel Fresno

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Chagas disease is caused by the protozoan Trypanosoma cruzi and is characterized by heart failure and sudden death. Identifying which factors are involved in evolution and treatment response is actually challenging.

Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias.

Methods

Sera from 38 chagasic patients were analyzed to determine the level of cytokines by Multiplexed Bead-Based Immunoassays. ANOVA test was applied to determine differences for each group. Additionally, a Linear Discriminant Analysis (LDA) was applied to observe the accuracy of different cytokines to discriminate between the groups.

Results

The levels of several cytokines were significantly higher in the high-risk of sudden death and untreated group. LDA showed that IL-2, IFN-γ and IL-10 were the best cytokines for discriminating between high-risk of sudden death and untreated patients versus low-risk of sudden death, treated and control groups.

Conclusions

High IL-2 levels seem to identify patients with high-risk of sudden death and seems adequate as treatment efficacy marker. To our knowledge, this is the first report about the anti-inflammatory role of the amiodarone in Chagas disease, suggesting an inmunomodulatory effect that may be exploited as coadjutant therapy in chronic Chagas disease.

Literature
  1. Jackson Y, Varcher Herrera M, Gascon J. Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe. Bull World Health Organ. 2014;92(10):771–2.View ArticlePubMedPubMed Central
  2. Salazar R, Castillo-Neyra R, Tustin AW, Borrini-Mayori K, Naquira C, Levy MZ. Bed Bugs (Cimex lectularius) as Vectors of Trypanosoma cruzi. AmJTrop Med Hyg. 2014;92(2):331–5.View Article
  3. Mendoza IMF, Marques J, Misticchio F, Matheus A. Rodriguez, A. Ventricular tachycardia in Chagas heart disease. Ital Card. 1999;29:247–50.
  4. Rassi Jr A, Rassi A, Marin-Neto JA. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Memorias do Instituto Oswaldo Cruz. 2009;104(Suppl 1):152–8.View ArticlePubMed
  5. Ribeiro AL, Cavalvanti PS, Lombardi F, Nunes Mdo C, Barros MV, Rocha MO;Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol 2008;19(5):502-509.
  6. Sousa GR, Gomes JA, Fares RC, Damasio MP, Chaves AT, Ferreira KS, Nunes MC, Medeiros NI, Valente VA, Correa-Oliveira R, et al. Plasma cytokine expression is associated with cardiac morbidity in chagas disease. PLoS One. 2014;9(3):e87082.View ArticlePubMedPubMed Central
  7. Guedes PM, Gutierrez FR, Silva GK, Dellalibera-Joviliano R, Rodrigues GJ, Bendhack LM, Rassi Jr A, Rassi A, Schmidt A, Maciel BC, et al. Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl Trop Dis. 2012;6(4):e1630.View ArticlePubMedPubMed Central
  8. da Matta Guedes PM, Gutierrez FR, Maia FL, Milanezi CM, Silva GK, Pavanelli WR, Silva JS. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis. 2010;4(2):e604.View ArticlePubMedPubMed Central
  9. Sanoja C, Carbajosa S, Fresno M, Girones N. Analysis of the dynamics of infiltrating CD4(+) T cell subsets in the heart during experimental Trypanosoma cruzi infection. PLoS One. 2013;8(6):e65820.View ArticlePubMedPubMed Central
  10. Dutra WO, Menezes CA, Magalhaes LM, Gollob KJ. Immunoregulatory networks in human Chagas disease. Parasite Immunol. 2014;36(8):377–87.View ArticlePubMedPubMed Central
  11. Leon JS, Wang K, Engman DM. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation. 2003;107(17):2264–9.View ArticlePubMed
  12. Coelho dos Santos JS, Menezes CA, Villani FN, Magalhaes LM, Scharfstein J, Gollob KJ, Dutra WO. Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells. Clin Exp Immunol. 2010;162(3):528–36.View ArticlePubMedPubMed Central
  13. Benaim G, Hernandez-Rodriguez V, Mujica-Gonzalez S, Plaza-Rojas L, Silva ML, Parra-Gimenez N, Garcia-Marchan Y, Paniz-Mondolfi A, Uzcanga G. In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother. 2012;56(7):3720–5.View ArticlePubMedPubMed Central
  14. Gali WL, Sarabanda AV, Baggio JM, Ferreira LG, Gomes GG, Marin-Neto JA, Junqueira LF. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. Europace. 2014;16(5):674–80.View ArticlePubMed
  15. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Jr., Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, et al. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med 2015;373(14):1295-1306.
  16. Poveda C, Fresno M, Girones N, Martins-Filho OA, Ramirez JD, Santi-Rocca J, Marin-Neto JA, Morillo CA, Rosas F, Guhl F. Cytokine profiling in Chagas disease: towards understanding the association with infecting Trypanosoma cruzi discrete typing units (a BENEFIT TRIAL sub-study). PLoS One. 2014;9(3):e91154.View ArticlePubMedPubMed Central
  17. Gil Flores J GJE, Rodríguez Gómez G. Análisis Discriminante, vol. 12. Madrid, España: Editorial La Muralla; 2001.
  18. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. A Trypanosoma cruzi DNA sequence amplified from inflammatory lesions in human chagasic cardiomyopathy. Trans Assoc Am Phys. 1992;105:182–9.PubMed
  19. Higuchi Mde L, De Brito T, Martins Reis M, Barbosa A, Bellotti G, Pereira-Barreto AC, Pileggi F. Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: Light microscopy and immunohistochemical findings. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 1993;2(2):101–6.View Article
  20. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49(4):1521–8.View ArticlePubMedPubMed Central
  21. Carmo AA, Rocha MO, Silva JL, Ianni BM, Fernandes F, Sabino EC, Ribeiro AL. Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease. Int J Cardiol. 2015;189:182–4.View ArticlePubMedPubMed Central
  22. Mendoza I, Camardo J, Moleiro F, Castellanos A, Medina V, Gomez J, Acquatella H, Casal H, Tortoledo F, Puigbo J. Sustained ventricular tachycardia in chronic chagasic myocarditis: electrophysiologic and pharmacologic characteristics. Am J Cardiol. 1986;57(6):423–7.View ArticlePubMed
  23. Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, Lannes-Vieira J. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease. Mediat Inflamm. 2014;2014:798078.View Article
  24. Nogueira LG, Santos RH, Fiorelli AI, Mairena EC, Benvenuti LA, Bocchi EA, Stolf NA, Kalil J, Cunha-Neto E. Myocardial gene expression of T-bet, GATA-3, Ror-gammat, FoxP3, and hallmark cytokines in chronic Chagas disease cardiomyopathy: an essentially unopposed TH1-type response. Mediat Inflamm. 2014;2014:914326.
  25. Cunha-Neto E, Teixeira PC, Fonseca SG, Bilate AM, Kalil J. Myocardial gene and protein expression profiles after autoimmune injury in Chagas’ disease cardiomyopathy. Autoimmun Rev. 2011;10(3):163–5.View ArticlePubMed
  26. Araujo-Jorge TC, Waghabi MC, Bailly S, Feige JJ. The TGF-beta pathway as an emerging target for Chagas disease therapy. Clin Pharmacol Ther. 2012;92(5):613–21.View ArticlePubMed
  27. Zhao Y, Sun Q, Zeng Z, Li Q, Zhou S, Zhou M, Xue Y, Cheng X, Xia Y, Wang Q, et al. Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells. BMC Cardiovasc Disord. 2016;16:1.View ArticlePubMedPubMed Central
  28. Aksyonov A, Mitrokhin VM, Mladenov MI. Effects of interleukin-2 on bioelectric activity of rat atrial myocardium under normal conditions and during gradual stretching. Immunol Lett. 2015;167(1):23–8.View ArticlePubMed
  29. Cabrera-Bueno F, Medina-Palomo C, Ruiz-Salas A, Flores A, Rodriguez-Losada N, Barrera A, Jimenez-Navarro M, Alzueta J. Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation. Cytokine. 2015;73(1):74–8.View ArticlePubMed
  30. de Carvalho AC, Masuda MO, Tanowitz HB, Wittner M, Goldenberg RC, Spray DC. Conduction defects and arrhythmias in Chagas' disease: possible role of gap junctions and humoral mechanisms. J Cardiovasc Electrophysiol. 1994;5(8):686–98.View ArticlePubMed
  31. Adesse D, Azzam EM, Meirelles Mde N, Urbina JA, Garzoni LR. Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob Agents Chemother. 2011;55(1):203–10.View ArticlePubMed
  32. Reis DD, Jones EM, Tostes Jr S, Lopes ER, Gazzinelli G, Colley DG, McCurley TL. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. AmJTrop Med Hyg. 1993;48(5):637–44.
  33. Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, Bocchi EA, Teixeira HC, Mady C, Kalil J, et al. Chronic Chagas’ disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun. 2001;17(1):99–107.View ArticlePubMed
  34. Reis MM, Higuchi Mde L, Benvenuti LA, Aiello VD, Gutierrez PS, Bellotti G, Pileggi F. An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin Immunol Immunopathol. 1997;83(2):165–72.View ArticlePubMed
  35. Steyers 3rd CM, Miller Jr FJ. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014;15(7):11324–49.View ArticlePubMedPubMed Central
  36. Silva-Filho JL, Souza MC, Henriques M, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA. AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol. 2011;48(15–16):1835–43.View ArticlePubMed
  37. Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interf Cytokine Res. 2009;29(6):327–32.View Article
  38. Rizos I, Tsiodras S, Rigopoulos AG, Dragomanovits S, Kalogeropoulos AS, Papathanasiou S, Sakadakis EA, Kremastinos DT. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine. 2007;40(3):157–64.View ArticlePubMed
  39. Cheng SM, Lin WH, Lin CS, Ho LJ, Tsai TN, Wu CH, Lai JH, Yang SP. Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodarone. Exp Biol Med. 2015;240(1):99–108.View Article
  40. Ozbakis-Dengiz G, Halici Z, Akpinar E, Cadirci E, Bilici D, Gursan N. Role of polymorphonuclear leukocyte infiltration in the mechanism of anti-inflammatory effect of amiodarone. Pharmacological reports: PR. 2007;59(5):538–44.PubMed
  41. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S. Interleukin-17. Int Rev Immunol. 1998;16(5–6):541–51.View ArticlePubMed
  42. Tanigaito Y, Sato K, Kitamura K, Suzuki A, Futase A, Shiga T, Hagiwara N. Abstract 15132: Amiodarone Treatments Improve the Inflammation in Heart Failure. Circulation. 2014;130(Suppl 2):A15132.
Metadata
Title
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status
Authors
Héctor Rodríguez-Angulo
Juan Marques
Ivan Mendoza
Marco Villegas
Alfredo Mijares
Núria Gironès
Manuel Fresno
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2324-x

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue

Research article

A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

Research article

Comparison of antibody responses against Mycobacterium tuberculosis antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study

Research article

Norovirus infections in young children in Lusaka Province, Zambia: clinical characteristics and molecular epidemiology

Research article

Sero-epidemiology study of leptospirosis in febrile patients from Terai region of Nepal

Research article

Relationships between sickle cell trait, malaria, and educational outcomes in Tanzania

Research article

Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits